BridgeBio Pharma, Inc. (BBIO) Current Ratio
- Current ratio · latest quarter: Value 1.23×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.23× | Current assets / current liabilities. $1.09B ÷ $890.65M ≈ 1.23× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.09B USD | Assets, Current |
| Current obligations | 890.65M USD | Liabilities, Current |
| Cash and equivalents | 677.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 42.25M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 254.48M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 52.84M USD | Inventory, Net |
| Payables | 27.20M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.09B | $890.65M | $677.91M | $42.25M | $254.48M | $52.84M | $27.20M | (m) | 1.23× |
| 2026-03-31 | $1.24B | $816.37M | $879.89M | $60.30M | $205.23M | $32.98M | $29.06M | (m) | 1.52× |
| 2025-12-31 | $797.75M | $287.97M | $570.12M | $17.36M | $139.44M | $26.75M | $36.23M | (m) | 2.77× |
| 2025-09-30 | $839.38M | $216.60M | $642.95M | $2.99M | $116.52M | $24.53M | $18.70M | (m) | 3.88× |
| 2025-06-30 | $912.28M | $175.85M | $748.95M | $7.94M | $76.87M | $18.28M | $26.13M | (m) | 5.19× |
| 2025-03-31 | $695.17M | $152.10M | $540.60M | (m) | $115.27M | $3.95M | $27.52M | (m) | 4.57× |
| 2024-12-31 | $720.69M | $154.40M | $681.10M | $0.00 | $4.72M | $0.00 | $9.62M | (m) | 4.67× |
| 2024-09-30 | $444.58M | $139.22M | $266.32M | (m) | (m) | (m) | $13.36M | (m) | 3.19× |
| 2024-06-30 | $616.24M | $134.36M | $407.96M | $39.81M | (m) | (m) | $18.13M | (m) | 4.59× |
| 2024-03-31 | $783.42M | $141.48M | $475.22M | $44.47M | (m) | (m) | $4.73M | (m) | 5.54× |
| 2023-12-31 | $477.59M | $143.84M | $375.94M | (m) | $1.75M | (m) | $10.65M | (m) | 3.32× |
| 2023-09-30 | $587.67M | $106.06M | $505.21M | $0.00 | (m) | (m) | $4.47M | (m) | 5.54× |
| 2023-06-30 | $432.88M | $110.12M | $302.44M | $30.87M | (m) | (m) | $3.87M | (m) | 3.93× |
| 2023-03-31 | $552.70M | $96.60M | $407.37M | $34.12M | (m) | (m) | $4.08M | (m) | 5.72× |
| 2022-12-31 | $548.85M | $121.43M | $376.69M | $51.58M | (m) | (m) | $11.56M | (m) | 4.52× |
| 2022-09-30 | $642.22M | $119.19M | $483.24M | $75.08M | (m) | (m) | $10.16M | (m) | 5.39× |
| 2022-06-30 | $771.28M | $141.16M | $470.10M | $218.47M | (m) | (m) | $8.79M | (m) | 5.46× |
| 2022-03-31 | $716.23M | $103.46M | $371.55M | $261.90M | (m) | (m) | $10.11M | (m) | 6.92× |
| 2021-12-31 | $888.86M | $135.07M | $393.77M | $393.74M | (m) | (m) | $11.88M | (m) | 6.58× |
| 2021-09-30 | $639.71M | $95.82M | $180.35M | $419.26M | (m) | (m) | $12.04M | (m) | 6.68× |
| 2021-06-30 | $909.87M | $131.91M | $378.42M | $459.24M | $1.21M | (m) | $22.33M | (m) | 6.90× |
| 2021-03-31 | $945.11M | $94.73M | $471.18M | $447.94M | (m) | (m) | $10.34M | $3.65M | 9.98× |
| 2020-12-31 | $642.82M | $95.65M | $356.08M | $251.01M | (m) | (m) | $8.95M | $1.46M | 6.72× |
| 2020-09-30 | $745.38M | $75.71M | $366.97M | $343.71M | (m) | (m) | $9.84M | (m) | 9.85× |
| 2020-06-30 | $861.93M | $92.64M | $540.92M | $300.02M | (m) | (m) | $12.84M | (m) | 9.30× |
| 2020-03-31 | $924.96M | $64.91M | $757.05M | $148.13M | (m) | (m) | $13.09M | (m) | 14.25× |
| 2019-12-31 | $568.62M | $60.38M | $363.77M | $182.22M | (m) | (m) | $8.85M | (m) | 9.42× |
| 2019-09-30 | $558.15M | $39.86M | $413.97M | $122.08M | (m) | (m) | $10.27M | (m) | 14.00× |
| 2018-12-31 | $445.22M | $32.58M | $436.09M | (m) | (m) | (m) | $13.51M | (m) | 13.67× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |